This slide deck describes results from a PATH project conducted to better understand the landscape of potential technologies for manufacturing polio vaccines from non-infectious sources, specifically S19, mRNA, and virus-like particle (VLP) platforms.

Vaccines manufactured from non-infectious sources are an important tool in the post polio-eradication era given remaining risks of accidental poliovirus release into the environment.

Results from the project provide in-depth information about the developability, acceptability and market demand for such next-generation polio vaccines.​ Articulating the relative pros and cons of each platform will help to guide future investment decisions. Key outputs analyzed include the following:

• The use case for future non-infectious polio vaccines
• Developability of the three potential non-infectious vaccine platforms
• The potential market and associated demand for a next-generation non-infectious polio vaccine
• Disease containment, including 1) guidelines for novel oral polio vaccines and S19, and 2) environmental and community impacts of accidental exposure under containment or temporary waived conditions (in progress)